**Supplemental material 1**

*List of collaborators*

\*Collaborators of the Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetology (ISPED). The following people were actively involved in the collection of data and in manuscript revision and have to be considered as coauthors of the paper:

Riccardo Lera MD, Giulia Patrizia Bracciolini MD, Caterina Grosso MD, Enrica Bertelli MD (Alessandria); Valentino Cherubini MD (Ancona); Elvira Piccinno MD, Maurizio Delvecchio MD, Federica Ortolani MD, Marcella Vendemiale PsyD, Alessandra Rutigliano PsyD (Bari); Clara Zecchino MD (Bari); Stefano Zucchini MD, Giulio Maltoni MD, Dorella Scarponi PsyD, Lucia Fraternale PsyD (Bologna); Francesco Gallo MD, Maria Susanna Coccioli MD, Vito Brugnola PsyD (Brindisi); Carlo Ripoli MD, Maria Rossella Ricciardi MD, Sabrina Maria Galassi MD (Cagliari); Filomena Pascarella MD, Angelo Perrotta MD, Anna Golino PsyD (Caserta); Filomena Andreina Stamati MD (Castrovillari); Donatella Lo Presti MD, Manuela Caruso Nicoletti MD, Annalisa Saggio PsyD (Catania); Felice Citriniti MD (Catanzaro); Domenico Sperlì MD, Rosaria De Marco MD, Maria Daniela Borselli PsyD (Cosenza); Nicola Lazzaro MD (Crotone); Valeria De Donno MD, Cristina Giordana PsyD (Cuneo); Sonia Toni MD, Verena Balbo PsyD (Florence); Giuseppe d'Annunzio MD, Nicola Minuto MD, Marta Bassi MD, Alice Parodi PsyD (Genoa); Mimma Caloiero MD, Monica Aloe MD, Maria Corsini PsyD (Lamezia Terme); Rosanna Lia MD (Locri); Fortunato Lombardo MD, Giuseppina Salzano MD, Stefano Passanisi MD, Maria Pecoraro PsyD (Messina); Riccardo Bonfanti MD, Clara Pozzi PsyD (Milan); Stefano Curto MD, Alessia Piscopo MD, Emanuele Miraglia del Giudice MD, Veronica Testa NDi, Assunta Serena Rollato NDi, Alessandro Pennarella MD (Naples); Ivana Rabbone MD, Ciro Pignatiello PsyD, Silvia Savastio MD, Valentina Antoniotti RDN (Novara); Fiorella De Berardinis MD, Giacomo Santoro MD (Paola Cetraro); Brunella Iovane MD, Silvia Dioni PsyD (Parma); Maria Carmela Lia MD, Rita Tutino PsyD (Reggio Calabria); Stefano Cianfarani MD, Riccardo Schiaffini MD, Ippolita Patrizia Patera MD, Maria Cristina Matteoli MD, Chiara Carducci PsyD (Rome); Irene Rutigliano MD, Grazia D'Onofrio PsyD (San Giovanni Rotondo, FG); Luisa de Santis MD, Michela Trada MD, Davide Tinti MD, Cinzia Montarulo PsyD (Turin); Giuliana Cardinale MD, Sofia De Leo PsyD (Casarano, Gallipoli); Claudia Arnaldi MD; Barbara Longo PsyD (Viterbo).

**Supplemental material 2**

*Comparison of participants with T1D and comorbid autoimmune conditions vs. those with only T1D*

The participants with T1D and comorbid autoimmune conditions did not differ from those with only T1D in terms of mean age (*F*(3,1561)=1.797, *p*=.146, *η2*= .003), SES level (*F*(3,1550)=1.875, *p*=.132, *η2*=.004), HbA1c values (*F*(3,1559)=.587, *p*=.624, *η2*=.001), zBMI (*F*(3,1562)=1.944, *p*=.121, *η2*=.004), or DEB prevalence (*F*(3,1561)=.641, *p*=.588, *η2*=.001). Gender was not equally distributed across group, with a lower number of boys in the thyroiditis group (χ2= 21.735, *p* ≤.0001). Duration of illness was longer in participants with celiac disease (*F*(3,1561)=11.397, *p* ≤ .0001, *η2*=.021) when compared with participants with only T1D (*p* ≤.0001) and participants with comorbid thyroiditis (*p* =.001); individuals with both celiac disease and thyroiditis have a longer duration of illness than those with only T1D (*p* =.035) and those with comorbid thyroiditis (*p*=.043)

**Supplemental material 3**

**Table S1**

*Correlations Among the Variables.*

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 1. Gender | - | -.13 | .05 | .11 | .18\*\* | .06 | .33\*\* | -.08 | .26\*\*\* | -.07 |
| 2. Age | -.01 | - | -.12 | -.04 | -.18\*\* | .10 | .08 | -.03 | -.01 | .02 |
| 3. SES | -.04 | -.001 | - | .19\*\* | -.01 | -.07 | -.02 | -.06 | -.10 | -.22\*\* |
| 4. Type of therapy | .04 | -.003 | .18\*\*\* | - | .11 | .04 | .17\* | -.01 | .06 | -.25\*\*\* a |
| 5. zBMI | .15\*\*\* | -.08\*\* | -.07\*\* | -.06\* | - | .04 | .01 | .05 | .26\*\*\* | .17\*\* |
| 6. Externalizing problems | .05 | .07\* | -.10\*\*\* | -.10\*\*\* | .07\* | - | .39\*\*\* | .39\*\*\* | .46\*\*\* | .10 |
| 7. Internalizing problems | .35\*\*\* | .04 | -.06\* | .02 | .07\* | .43\*\*\* | - | .18\*\* | .46\*\*\* | -.03 |
| 8. IM  | .01 | .04 | -.05 | -.03 | -.04 | .31\*\*\* | .22\*\*\* | - | .50\*\*\* | .30\*\*\* |
| 9. DE | .27\*\*\* | .03 | -.14\*\*\* | -.10\*\*\*b | .25\*\*\* | .46\*\*\* | .49\*\*\* | .48\*\*\* | - | .30\*\*\* |
| 10. HbA1c  | .09\*\*a | -.009 | -.20\*\*\* | -.25\*\*\*c | .08\*\* | .24\*\*\* | .10\*\*\* | .30\*\*\* | .35\*\*\* | - |

*Note.* Correlations for patients with only T1D are below the diagonal, correlations for patients with T1D and other diseases (celiac diseases and/or thyroiditis) are above the diagonal. Gender was coded as 1 = males, 2 = females. Type of therapy was coded as 1 = multiple daily injections (MDI), 2 = continuous subcutaneous insulin infusion (CSII). IM= insulin manipulation (sum of scores to DEPS-r’s item 2 and 8); DE= disordered eating (sum of all scores to DEPS-r’s item excluding 2 and 8).

a higher HbA1c was associated with being female

b higher DE was associated with MDI

c higher HbA1c was associated with MDI

\**p*≤.05; \*\**p*≤.01; \*\*\**p*≤.001.